CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

doi:10.1016/j.neuropharm.2006.07.024

Paper

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

Published Feb 1, 2007 · J. Siuciak, D. Chapin, S. McCarthy

Neuropharmacology

Q1 SJR score

133

Citations

15

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Highly Cited

Study Snapshot

CP-809,101 shows potential in treating psychosis and improving cognitive dysfunction in schizophrenia with low extrapyramidal symptom liability.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity

References

Citations